Home > Physicians > Medical Education > Med Ed Programs > MDS Treatment Advances: Applying new data for decision-making

CME Program

MDS Treatment Advances: Applying new data for decision-making

MDS Treatment Advances Online Program
Available after July 21, 2008

Order CD

MDS Treatment Advances CD
Available after July 21, 2008

Program Description

Recent advances in both drug and transplant therapies provide new options for treating patients with myelodysplastic syndrome (MDS). Dr. Richard Stone will discuss novel drug agents and their potential application. Dr. Corey Cutler will discuss advances in transplantation and outcomes. From these two perspectives, the two paths will be compared, with patient eligibility defined for both. Using interactive case studies, they will also discuss their collaborative approach in defining a patient’s treatment strategy.

Faculty

Corey Cutler, M.D. MPH FRCP(C)
Assistant Professor of Medicine
Harvard Medical School
Department of Medical Oncology/Hematologic Malignancies
Dana-Farber Cancer Institute

Richard Stone, M.D.
Associate Professor of Medicine
Harvard Medical School
Department of Medical Oncology/Hematologic Malignancies
Dana-Farber Cancer Institute

Learning Objectives

Describe application of newer drug therapies that may affect clinical practice
Define the role and timing of transplantation in treatment decision-making
Define patient eligibility in older patients for drug and transplant therapies, including the use of reduced-intensity regimens
Describe the collaborative approach in working together to define a patient’s treatment strategy

Goal

The goal of this program is to enhance clinical decision-making through education on MDS therapeutic advances that affect patient eligibility.

Target Audience

Physicians who treat patients for hematologic malignancies and who may refer for transplantation.

Accreditation and Certification

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical College of Wisconsin and the National Marrow Donor Program^® (NMDP). The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy:

It is the policy of the Medical College of Wisconsin Office of Continuing Medical Education to ensure balance, independence, objectivity and scientific rigor in all of its sponsored educational activities. All planners and faculty participating in accredited CME activities have disclosed their relevant financial relationships, and any real or apparent conflicts of interest related to the content of their presentations have been identified and resolved. The audience shall be informed of all relevant financial relationships, including the source of any commercial support for this forum.

Questions

If you have any questions regarding this program, call Renee Ryan at (800) 526-7809 ext. 8430, or e-mail to rryan@nmdp.org

E-mail a Friend

Print this Page